Aurora Cannabis Inc.·Healthcare

The Canadian cannabis sector continues to evolve in 2026, even as volatility remains elevated. Total Canadian cannabis sales have steadily increased in recent years, showing consistent demand growth. However, pricing pressure and competition continue to challenge margins across the industry. Still, leading companies are adapting through international expansion, scale in retail, and diversification. As a result, investors are closely watching key names for potential upside during sector recoveries.

NASDAQ | TSX: ACB The Globe and Mail's Report on Business Women Lead Here List acknowledges Aurora's commitment to inclusive leadership at the executive level EDMONTON, AB, March 30, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian‑based leading global medical cannabis company, has been named on The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year. The annual editorial benchmark recognizes publicly traded Canadian companies demonstrating strong executive‑level gender diversity, underscoring Aurora's continued commitment to inclusive leadership.

The cannabis industry has made a tremendous impact on the world. From being once a taboo subject to now a well-respected and much more accepted industry. Even the thought of what may happen to a legal operator could shape the way marijuana stock investors think. At one point during the green rush, the fear of what could happen with no federal reform would shift how the market reacted. But as of 2026, those fears and worries have calmed down a lot.

Marijuana stocks, even with their volatile behavior, still offer diverse investment opportunities. Not every sector or company deals directly with the plant, so investors see this as an opportunity to capitalize. Now, even with that said, MSO and companies that work directly with the plant tend to capture more market share. Also, they are usually the first to see a run in trading when the time comes.

Aurora Cannabis has had a terrible track record in recent years. Even if recent regulatory changes in the U.S. cause a new pot boom, Aurora is unlikely to capitalize on it.

NASDAQ | TSX: ACB Canada's Largest Global Medical Cannabis Company to Discuss Growth Strategy, Key Trends and Market Opportunities EDMONTON, AB, Feb. 17, 2026 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, will participate in TD Cowen's 46th Annual Health Care Conference in Boston, MA. Simona King, Chief Financial Officer at Aurora, will take part in a fireside chat and one-on-one meetings with investors on March 2, 2026.
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Healthcare
Drug Manufacturers - Specialty & Generic
1,073
2014-07-15
1.32